LIVN - リバノバ (LivaNova PLC)

LIVNのニュース

   Active Implantable Medical Devices Market by Growing Technology Trends and Analysis 2025 - Lead by ABBOTT, Cochlear, BIOTRONIK, MED-EL, SONOVA and LivaNova  2020/10/09 14:01:46 OpenPR
Active Implantable Medical Devices Market was valued at US$ 22,096.9 Mn in 2017 and is estimated to reach US$ 39,026.9 Mn by 2025. The market is estimated to grow with a CAGR of 7.9% from 2018-2025. The report highlights
   Comprehensive Report on Organ Perfusion System Market Set to Witness Huge Growth by 2026 | Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), and more  2020/10/05 11:07:41 OpenPR
Reports and Data has added a new report titled Global Organ Perfusion System Market to its ever-expanding repository, which aims to offers valuable insights into the Organ Perfusion System industry with regards to the market share, market size, market valuation,
   Cardiac Medical Devices Global Market Future Scope, Opportunities with Strategic Growth and Top Players are LivaNova, Medtronic, Abbott, Biotronik, Getinge, Terumo  2020/10/05 10:22:50 OpenPR
Scope of the Study: Cardiac Medical Devices Market (COVID 19 Impact Analysis) is a research that features comprehensive outlook pertaining to market valuations, market share, profit estimations, and the geographical spectrum of this business. The report precisely describes key obstacles and
   Extracorporeal Membrane Oxygenation (ECMO) Market 2020-2027 study and future prospects including key players LivaNova PLC, XENIOS AG, Terumo Corporation, MicroPort Scientific Corporation, etc.  2020/10/01 19:13:11 OpenPR
Reports and Data has released a new market report titled “Global Extracorporeal Membrane Oxygenation (ECMO) Market” which is an extensive study of the Extracorporeal Membrane Oxygenation (ECMO) market spanning over 100+ pages with pictorial representations of key statistical data. The
   LivaNova to Host Conference Call for Third Quarter 2020 Results  2020/09/28 13:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m. London (8 a.m. EDT).
   LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression  2020/03/09 13:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today announced its VNS Therapy® System, Symmetry™, earned CE Mark approval for Difficult-to-Treat Depression.
   LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression  2020/02/26 21:44:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC announced a research collaboration with Verily, an Alphabet company, to capture measures of depression within its RECOVER clinical study.
   LivaNova Reports Fourth Quarter and Full-Year 2019 Results  2020/02/26 11:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today reported results for the quarter and full-year ended December 31, 2019.
   LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification  2020/02/25 19:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC announced it received U.S. FDA 510(k) clearance for a device modification to its 3T Heater-Cooler® devices.
   New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”  2020/02/19 14:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova commends the international consensus statement published in the Journal of Affective Disorders regarding Difficult-to-treat Depression.
   LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression  2020/02/26 21:44:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC announced a research collaboration with Verily, an Alphabet company, to capture measures of depression within its RECOVER clinical study.
   LivaNova Reports Fourth Quarter and Full-Year 2019 Results  2020/02/26 11:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today reported results for the quarter and full-year ended December 31, 2019.
   LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification  2020/02/25 19:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC announced it received U.S. FDA 510(k) clearance for a device modification to its 3T Heater-Cooler® devices.
   New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”  2020/02/19 14:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova commends the international consensus statement published in the Journal of Affective Disorders regarding Difficult-to-treat Depression.
   LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results  2020/01/28 14:00:00 Business Wire
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its fourth quarter and full-year 2019 results on Feb. 26, 2020 at 1 p.m. London (8 a.m. EST).

calendar